Indications |
Subcutaneous Prophylaxis of deep vein thrombosis Adult: Initially 50 iu/kg following surgery. Subsequently, 50 iu/kg bid for 14 days after surgery or until ambulatory. |
Contraindications |
Hypersensitivity, thrombocytopaenia, active major bleeding, active peptic ulcer. |
Warnings / Precautions |
Renal or hepatic impairment, history of GI ulceration, uncontrolled hypertension, spinal or epidural anaesthesia. Pregnancy, lactation; elderly. Periodic blood counts, including platelet count and stool occult blood test recommended. |
Adverse Reactions |
Thrombocytopaenia, mild bleeding, Inj site irritation, pain and ecchymoses, hypersensitivity and erythema. Potentially Fatal: Haemorrhagic complications. |
Drug Interactions |
Potentially Fatal: Risk of haemorrhage increased with oral anticoagulants, platelet aggregation inhibitors, NSAIDs including aspirin. See Below for More ardeparin Drug Interactions |
Mechanism of Actions |
Ardeparin Na is a LMWH with anticoagulant activity. It has been used for the prevention of post-op venous thromboembolism. Excretion: Elimination half-life: 3.5 hr. |
Available As |
|
Ardeparin
Post Review about Ardeparin Click here to cancel reply.
Ardeparin Containing Brands
Ardeparin is used in following diseases
Drug - Drug Interactions of Ardeparin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.